In mid-February, Health Canada sent a letter reminding all Drug Establishment Licence (DEL) holders of their GMP responsibilities. The letter advises DEL holders that the agency intends to increase the frequency of planned and unplanned inspections of facilities.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
